Disability

Parexel Releases 2023 Environmental, Social and Governance Report

DURHAM, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the…

1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

1 year ago

NAVIGANTIS Secures $12 Million to Advance the Development of its VASCO Robotic Platform

MIAMI, July 25, 2024 /PRNewswire/ -- NAVIGANTIS Inc. announced today that it has closed a $12 million Series A financing led…

1 year ago

New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12

Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and…

1 year ago

30 Days to Greater Impact: Voiceitt’s Free Trial Empowers Therapists to Help Clients with Non-Standard Speech

Speech Recognition Startup Announces New Program for Speech Pathologists and Other Therapy Professionals to Expand the Impact of its Inclusive Voice AI…

1 year ago

Policymakers should recognise #SelfCareIsHealthcare in campaign bid to address global health challenges

Self-care is healthcare Self-care is healthcare Self-care describes the role of individuals in preventing disease, promoting and maintaining their mental…

1 year ago

Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome

U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X Syndrome SPG601 is a novel…

1 year ago

Elucid Names Kelly Huang as CEO

Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis softwareBOSTON--(BUSINESS WIRE)--Elucid, a…

1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had…

1 year ago